Strata

PUBLICATIONS

Research and publications

Explore research and publications from the Strata team and our collaborators.

2025American Journal of Psychiatry

Compass psychological support model for COMP360 psilocybin treatment of serious mental health conditions.

Kirlić, N., Lennard-Jones, M., Atli, M., Malievskaia, E., Modlin, N. L., Peck, S. K., ... & Koelpin, D.

182(1), 126–132

2022New England Journal of Medicine

Single-dose psilocybin for a treatment-resistant episode of major depression.

Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., ... Knatz Peck, S. & Malievskaia, E.

387(18), 1637–1648

2023Nature Medicine

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study.

Peck, S. K., Shao, S., Gruen, T., Yang, K., Babakanian, A., Trim, J., ... & Kaye, W. H.

29(8), 1947–1953

Read publication
2023Neuropsychopharmacology

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., ... Knatz Peck, S. & Malievskaia, E.

Showing 4 of 13

Shaping Professional Standards

Strata’s founders contribute to the scholarship and professional guidance shaping psychedelic care in the United States and the United Kingdom.

2026American Psychiatric Association Publishing

Psychedelic Treatment for Emerging Indications: Eating Disorders, Autism, and Chronic Pain Management

Authored by Strata co-founder Stephanie Knatz Peck, PhD, this chapter appears in Psychedelics: Transforming Psychiatry, published by American Psychiatric Association Publishing in 2026.

Knatz Peck, S., Spriggs, M., Lafrance, A., Whelan, T. P., McAlonan, G. M., Lii, T. R., Woolley, J. D., & Heifets, B. D. (2026). Psychedelic treatment for emerging indications: Eating disorders, autism, and chronic pain management. In S. T. Aaronson, A. Garcia-Romeu, & T. Suppes (Eds.), Psychedelics: Transforming psychiatry. American Psychiatric Association Publishing.

2025Royal College of Psychiatrists Research Guidance

Psychoanalytic Formulations in Psychedelic Therapy for Treatment-Resistant Depression (TRD)

The Royal College of Psychiatrists cites Psychoanalytic Formulations in Psychedelic Therapy for Treatment-Resistant Depression (TRD), authored by Strata co-founder Carolina Maggio, in Guidance for Practice: Working Therapeutically with PARS, Section 4: “Working with Non-Ordinary States”.

Maggio, C., Fischer, F. M., Modlin, N. L., & Rucker, J. (2023). Psychoanalytic formulations in psychedelic therapy for treatment resistant depression (TRD). Journal of Psychology & Psychotherapy, 13(4), 1000456.

Read the Royal College of Psychiatrists guidance

FREQUENTLY ASKED QUESTIONS

Questions about working with Strata?

Explore some of the questions we hear most often about our approach, implementation support, and clinical partnerships.

Strata partners with your mental health organization to implement emerging treatment models through training, clinical preparation, safety frameworks, and ongoing support.

Strata works with health networks, clinics, clinical teams, and organizations bringing new mental health treatments into practice.

Implementation support can include competency-based training, safety preparation, clinical workflows, credentialing, and post-credentialing support.

Strata stays alongside clinical teams beyond initial training, providing ongoing support as teams begin treating patients and integrate new approaches into their clinical practice.

The Strata team has extensive experience delivering COMP360 and training providers in the Compass clinical trials. Strata is a recipient of an educational grant from Compass Pathways to develop training that translates clinical trial rigor to scalable, real-world practice.